COVID-19 vaccine Covaxin's Phase-3 human trials began at All India Institute of Medical Science (AIIMS) in New Delhi on Thursday.

TOP INSIGHT
Covaxin, India's indigenous coronavirus vaccine by Bharat Biotech, is developed in collaboration with the ICMR - National Institute of Virology (NIV).
It is the biggest clinical trial conducted for a coronavirus vaccine in India.
Trial volunteers will take two intramuscular injections approximately 28 days apart. Participants will be randomly assigned to get Covaxin or placebo. The trial is double-blinded, where the investigators, the participants, and the company will not be aware of who is assigned to which group.
Covaxin has been evaluated in 1,000 subjects in Phase-1 and Phase-2 clinical trials, promising safety and immunogenicity data. Volunteers who wish to join in this trial should be adults over 18 years of age.
MEDINDIA




Email










